260 related articles for article (PubMed ID: 28393712)
21. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
Gillard M; Chatelain P; Fuks B
Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440
[TBL] [Abstract][Full Text] [Related]
22. Kindling-associated SV2A expression in hilar GABAergic interneurons of the mouse dentate gyrus.
Ohno Y; Okumura T; Terada R; Ishihara S; Serikawa T; Sasa M
Neurosci Lett; 2012 Feb; 510(2):93-8. PubMed ID: 22266237
[TBL] [Abstract][Full Text] [Related]
23. Expression profile of synaptic vesicle glycoprotein 2A, B, and C paralogues in temporal neocortex tissue from patients with temporal lobe epilepsy (TLE).
Pazarlar BA; Aripaka SS; Petukhov V; Pinborg L; Khodosevich K; Mikkelsen JD
Mol Brain; 2022 May; 15(1):45. PubMed ID: 35578248
[TBL] [Abstract][Full Text] [Related]
24. Differential expression of SV2A in hippocampal glutamatergic and GABAergic terminals during postnatal development.
Vanoye-Carlo A; Gómez-Lira G
Brain Res; 2019 Jul; 1715():73-83. PubMed ID: 30905653
[TBL] [Abstract][Full Text] [Related]
25. Low distribution of synaptic vesicle protein 2A and synaptotagimin-1 in the cerebral cortex and hippocampus of spontaneously epileptic rats exhibiting both tonic convulsion and absence seizure.
Hanaya R; Hosoyama H; Sugata S; Tokudome M; Hirano H; Tokimura H; Kurisu K; Serikawa T; Sasa M; Arita K
Neuroscience; 2012 Sep; 221():12-20. PubMed ID: 22766234
[TBL] [Abstract][Full Text] [Related]
26. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events.
Romoli M; Mandarano M; Romozzi M; Eusebi P; Bedetti C; Nardi Cesarini E; Verzina A; Calvello C; Loreti E; Sidoni A; Giovenali P; Calabresi P; Costa C
J Neurol; 2019 Sep; 266(9):2273-2276. PubMed ID: 31168673
[TBL] [Abstract][Full Text] [Related]
27. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
[TBL] [Abstract][Full Text] [Related]
28. Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands.
Mercier J; Archen L; Bollu V; Carré S; Evrard Y; Jnoff E; Kenda B; Lallemand B; Michel P; Montel F; Moureau F; Price N; Quesnel Y; Sauvage X; Valade A; Provins L
ChemMedChem; 2014 Apr; 9(4):693-8. PubMed ID: 24446373
[TBL] [Abstract][Full Text] [Related]
29. Connectivity Mapping Using a Novel
Zhang Y; Heylen L; Partoens M; Mills JD; Kaminski RM; Godard P; Gillard M; de Witte PAM; Siekierska A
Front Mol Neurosci; 2022; 15():881933. PubMed ID: 35686059
[TBL] [Abstract][Full Text] [Related]
30. Down-regulation synaptic vesicle protein 2A in the anterior temporal neocortex of patients with intractable epilepsy.
Feng G; Xiao F; Lu Y; Huang Z; Yuan J; Xiao Z; Xi Z; Wang X
J Mol Neurosci; 2009 Nov; 39(3):354-9. PubMed ID: 19757204
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain.
Nabulsi NB; Mercier J; Holden D; Carré S; Najafzadeh S; Vandergeten MC; Lin SF; Deo A; Price N; Wood M; Lara-Jaime T; Montel F; Laruelle M; Carson RE; Hannestad J; Huang Y
J Nucl Med; 2016 May; 57(5):777-84. PubMed ID: 26848175
[TBL] [Abstract][Full Text] [Related]
32. Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment.
Contreras-García IJ; Gómez-Lira G; Phillips-Farfán BV; Pichardo-Macías LA; García-Cruz ME; Chávez-Pacheco JL; Mendoza-Torreblanca JG
Brain Sci; 2021 Apr; 11(5):. PubMed ID: 33922424
[TBL] [Abstract][Full Text] [Related]
33. Brivaracetam prevents astroglial l-glutamate release associated with hemichannel through modulation of synaptic vesicle protein.
Okada M; Fukuyama K; Shiroyama T; Ueda Y
Biomed Pharmacother; 2021 Jun; 138():111462. PubMed ID: 33706129
[TBL] [Abstract][Full Text] [Related]
34. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
Wood MD; Gillard M
Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
[TBL] [Abstract][Full Text] [Related]
35. Epilepsy caused by an abnormal alternative splicing with dosage effect of the SV2A gene in a chicken model.
Douaud M; Feve K; Pituello F; Gourichon D; Boitard S; Leguern E; Coquerelle G; Vieaud A; Batini C; Naquet R; Vignal A; Tixier-Boichard M; Pitel F
PLoS One; 2011; 6(10):e26932. PubMed ID: 22046416
[TBL] [Abstract][Full Text] [Related]
36. An Epilepsy-Associated SV2A Mutation Disrupts Synaptotagmin-1 Expression and Activity-Dependent Trafficking.
Harper CB; Small C; Davenport EC; Low DW; Smillie KJ; Martínez-Mármol R; Meunier FA; Cousin MA
J Neurosci; 2020 Jun; 40(23):4586-4595. PubMed ID: 32341095
[TBL] [Abstract][Full Text] [Related]
37. Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding.
Shi J; Anderson D; Lynch BA; Castaigne JG; Foerch P; Lebon F
Biochem Soc Trans; 2011 Oct; 39(5):1341-7. PubMed ID: 21936812
[TBL] [Abstract][Full Text] [Related]
38. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM
Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120
[TBL] [Abstract][Full Text] [Related]
39. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
Wood MD; Sands ZA; Vandenplas C; Gillard M
Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
